JPRN-UMIN000036856已完成2 期
Phase II study of immunotherapy and cytotoxic agent in combination with palliative radiotherapy in patients with advanced non-small cell lung cancer - Phase II study of immunotherapy and cytotoxic agent in combination with palliative radiotherapy in patients with advanced non-small cell lung cancer
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 38
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1)Presence of EGFR mutation, ALK fusion gene, ROS1 fusion gene or BRAF mutation 2)Prior immunotherapy or radiotherapy 3)Symptomatic brain metastases 4)Patient with autoimmune disease 5)Patient with history of organ transplantation 6)Severe complication (uncontrolled heart failure, renal failure, chronic liver failure, diabetes mellitus, intestinal obstruction, active gastrointestinal ulceration, etc.) 7)Positive for hepatitis B surface (HBs) antigen or detectable HB virus DNA with positive for HBs antibody or hepatitis B core antibody 8)Radiographically confirmed interstitial pneumonitis 9)Receiving continuous systemic corticosteroid or immunosuppressant treatment or within 2 weeks after discontinuation 10)Pleural effusion, ascites or pericardial effusion requiring drainage 11)Pregnant or lactating females, females of child-bearing potential, and males desiring partner's pregnancy 12)Patient with active double cancer. (Exclude disease free interval over 5 years and carcinoma in situ) 13)History of severe drug allergies 14)Other ineligible status judged by attending doctor
研究者
相似试验
进行中（未招募）
不适用
A Phase II trial evaluating the immunological and clinical efficay and safety of HER-2 Protein Autovac(TM) monotherapy in patients with metastatic breast cancer - NAFemale patients with histologically proven metastatic or locally advanced breast cancer who have HER-2 overexpression in the primary tumour and/or a metastatic lesion.EUCTR2004-000838-36-HUPharmexa A/S60
进行中（未招募）
不适用
A Phase II trial evaluating the immunological and clinical efficacy and safety of HER-2 Protein AutoVac(TM) and Stimulon® Adjuvant QS-21 monotherapy in patients with metastatic breast cancerEUCTR2005-000558-60-HUPharmexa A/S60
进行中（未招募）
不适用
Pilot phase II study of a combined immunotherapy protocol based on oral vaccination and direct intratumoral injection of Salmonella Typhi Ty21a Vivotif in metastatic cutaneous melanoma patients. - NDMetastatic stage III e IV M1a melanomaMedDRA version: 6.1Level: PTClassification code 10042551EUCTR2005-005775-15-ITISTITUTO EUROPEO DI ONCOLOGIA43
进行中（未招募）
不适用
Phase II multicenter study of immuno-chemotherapy with fludarabine, cyclophosphamide and rituximab (FCR) for symptomatic Waldenstrom's macroglobulinemiaEUCTR2005-000174-52-ITASSOCIAZIONE MALATTIE SANGUE
已完成
2 期
Prostate Cancer: An internal, solid-malignancy model for vaccine therapyHormone refractory prostate cancerCancer - ProstateACTRN12605000589684Queensland Institute of Medical Research (QIMR)30